Literature DB >> 1421823

The manufacturing process of recombinant factor VIII, recombinate.

E Gomperts1, R Lundblad, R Adamson.   

Abstract

In summary, this brief report documents the cell culture and rAHF purification systems used to produce rFVIII and has focused on the unique characteristics of the cell line, the production process, and purification system used. This review emphasizes the general philosophy used throughout the research and development of this innovative and complex therapeutic agent, in order to provide a safe and efficacious rAHF in the management of individuals with hemophilia A. This review provides a brief description of the in-process system and controls that have been incorporated to meet the high standards and safety objective.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1421823     DOI: 10.1016/s0887-7963(92)70175-8

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  7 in total

1.  Evaluation of genetic stability of recombinant human factor VIII by peptide mapping and on-line mass spectrometric analysis.

Authors:  M J Besman; D Shiba
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 2.  Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.

Authors:  Jeanne M Lusher; Inge Scharrer
Journal:  Int J Hematol       Date:  2009-11-03       Impact factor: 2.490

Review 3.  Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients--impact on the immune and other systems.

Authors:  M C Poon
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

4.  Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.

Authors:  Min Xuan; Feng Xue; Rongfeng Fu; Yanhui Yang; Lei Zhang; Mengsu Tian; Renchi Yang
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

Review 5.  Prevention and Management of Bleeding Episodes in Children with Hemophilia.

Authors:  Rolf C R Ljung
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

Review 6.  Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.

Authors:  Mario Schiavoni; Mariasanta Napolitano; Gaetano Giuffrida; Antonella Coluccia; Sergio Siragusa; Valeria Calafiore; Giuseppe Lassandro; Paola Giordano
Journal:  Front Med (Lausanne)       Date:  2019-12-03

7.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.